13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q3 2022. See the latest, Q2 2026 →
Reported value
$1.96B
+6.3% on the quarter before
Positions
49
0 new · 6 sold out
Top 10
78.4%
of the value
Est. gain
+$259.2M
on stocks held all quarter
Est. return
+15.7%
on those stocks since Q2 2022
Positions as of Sep 30, 2022, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2022. Striped tiles are options.
Largest buys
Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Duolingo Inc.~$53.3MAdded · 0.7% → 3.4%+560,000 shares
Largest sells
Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$176.2MCut · 16.9% → 8.2%−2,188,154 shares
- Toast~$18.5MSold out · 1.0% → 0.0%−1,432,660 shares
- Ideaya Biosciences Inc~$10.4MSold out · 0.6% → 0.0%−753,187 shares
- Singular Genomics Systems Inc~$2.2MSold out · 0.1% → 0.0%−586,584 shares
- Velo3d Inc~$1.8MCut · 0.4% → 1.0%−461,671 shares
- Enjoy Technology Inc~$943,000Sold out · 0.1% → 0.0%−4,345,340 shares
- SentinelOne~$495,000Sold out · 0.0% → 0.0%−21,231 shares
- Wework Inc~$319,000Sold out · 0.0% → 0.0%−63,645 shares
Holdings
As of Sep 30, 2022. Changes are in shares against Jun 30, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics IncCOM · shares 0% · price +124.8% | 19.2% | $377.0M | +$209.3M | ||||||||
| Eqrx IncCOM · shares 0% · price +5.5% | 12.0% | $235.4M | +$12.4M | ||||||||
| UiPathCL A · shares 0% · price −30.7% | 9.1% | $177.4M | −$78.5M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price +25.4% | 8.9% | $173.4M | +$35.1M | ||||||||
| Dexcom IncCOM · shares −52% · price +8.1% | 8.2% | $161.1M | +$12.0M | ||||||||
| Oscar Health IncCL A · shares 0% · price +17.4% | 6.1% | $120.0M | +$17.8M | ||||||||
| SnowflakeCL A · shares 0% · price +22.2% | 4.6% | $91.0M | +$16.5M | ||||||||
| Lyft IncCL A COM · shares 0% · price −0.8% | 4.1% | $80.8M | −$676,000 | ||||||||
| Duolingo Inc.CL A COM · shares +388% · price +8.8% | 3.4% | $67.1M | +$1.1M | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price −1.4% | 2.7% | $52.3M | −$726,000 | ||||||||
| RobinhoodCOM CL A · shares 0% · price +22.9% | 2.5% | $49.8M | +$9.3M | ||||||||
| Lyell Immunopharma Inc.COM · shares 0% · price +12.4% | 2.2% | $43.0M | +$4.8M | ||||||||
| Benson Hill Inc.COMMON STOCK · shares 0% · price 0.0% | 2.1% | $42.1M | $0.00 | ||||||||
| Relay Therapeutics IncCOM · shares 0% · price +33.6% | 1.8% | $35.1M | +$8.8M | ||||||||
| Gitlab Inc.CLASS A COM · shares 0% · price −3.6% | 1.6% | $30.4M | −$1.1M | ||||||||
| Desktop Metal Inc.COM CL A · shares 0% · price +17.7% | 1.5% | $28.6M | +$4.3M | ||||||||
| Velo3d IncCOMMON STOCK · shares −8.6% · price +185.5% | 0.99% | $19.3M | +$12.5M | ||||||||
| 23andme Holding Co.CLASS A COM · shares 0% · price +15.3% | 0.98% | $19.3M | +$2.6M | ||||||||
| Invivyd Inc.COM · shares 0% · price −4.6% | 0.91% | $17.8M | −$852,000 | ||||||||
| Sana Biotechnology Inc.COM · shares 0% · price −6.7% | 0.86% | $16.9M | −$1.2M | ||||||||
| Beam Therapeutics Inc.COM · shares 0% · price +23.1% | 0.78% | $15.3M | +$2.9M | ||||||||
| Rapt Therapeutics Inc.COM · shares 0% · price +31.8% | 0.66% | $13.0M | +$3.1M | ||||||||
| Monte Rosa Therapeutics Inc.COM · shares 0% · price −15.5% | 0.61% | $12.0M | −$2.2M | ||||||||
| Illumina Inc.COM · shares 0% · price +3.5% | 0.52% | $10.2M | +$344,000 | ||||||||
| Rani Therapeutics Hldgs Inc.COM CL A · shares 0% · price −7.2% | 0.35% | $6.8M | −$535,000 | ||||||||
| Total · 49 positions | 100% | $1.96B | +$259.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2022 to Q3 2022: 49 stocks held throughout, up $259.2M (+15.7%).
- Verve Therapeutics Inc+$209.3M+125%
- Planet Labs Pbc+$35.1M+25%
- Oscar Health Inc+$17.8M+17%
- Snowflake+$16.5M+22%
- Velo3d Inc+$12.5M+186%
- Vaccitech Plc−$1.9M−28%
- Monte Rosa Therapeutics Inc.−$2.2M−16%
- Tenaya Therapeutics Inc.−$2.5M−48%
- Foghorn Therapeutics Inc.−$2.5M−37%
- UiPath−$78.5M−31%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |